Quoin Pharmaceuticals (NASDAQ:QNRX) Posts Earnings Results

Quoin Pharmaceuticals (NASDAQ:QNRX) posted its quarterly earnings data on Friday. The company reported ($1.90) EPS for the quarter, missing the consensus estimate of ($1.83) by ($0.07), Zacks reports.

Quoin Pharmaceuticals Trading Down 15.9%

Shares of NASDAQ QNRX opened at $5.09 on Friday. Quoin Pharmaceuticals has a 12 month low of $3.25 and a 12 month high of $41.80. The company has a 50 day simple moving average of $4.55 and a two-hundred day simple moving average of $6.12. The stock has a market cap of $10.23 million, a price-to-earnings ratio of -0.17 and a beta of 1.50.

Institutional Trading of Quoin Pharmaceuticals

Hedge funds and other institutional investors have recently made changes to their positions in the business. ADAR1 Capital Management LLC acquired a new position in Quoin Pharmaceuticals during the fourth quarter valued at $840,000. Boothbay Fund Management LLC purchased a new stake in Quoin Pharmaceuticals in the fourth quarter valued at $863,000. SummitTX Capital L.P. acquired a new stake in Quoin Pharmaceuticals during the 4th quarter worth about $935,000. Millennium Management LLC purchased a new position in shares of Quoin Pharmaceuticals during the 4th quarter valued at about $1,080,000. Finally, Ikarian Capital LLC purchased a new position in shares of Quoin Pharmaceuticals during the 4th quarter valued at about $3,052,000. Institutional investors and hedge funds own 8.63% of the company’s stock.

Wall Street Analyst Weigh In

A number of brokerages recently issued reports on QNRX. Weiss Ratings restated a “sell (e+)” rating on shares of Quoin Pharmaceuticals in a research note on Monday, July 20th. ThinkEquity assumed coverage on Quoin Pharmaceuticals in a research note on Monday, June 15th. They set a “buy” rating on the stock. One analyst has rated the stock with a Buy rating and one has issued a Sell rating to the company’s stock. Based on data from MarketBeat.com, Quoin Pharmaceuticals presently has a consensus rating of “Hold”.

About Quoin Pharmaceuticals

Quoin Pharmaceuticals, Ltd., a clinical stage specialty pharmaceutical company, focuses on the development and commercialization of therapeutic products for rare and orphan diseases. Its lead product is QRX003, a topical lotion to treat Netherton Syndrome (NS). The company is also developing QRX004 for the treatment of recessive dystrophic epidermolysis bullosa; QRX007 to treat NS; and QRX008 for the treatment of scleroderma. It has a research agreement with Queensland University of Technology; a license agreement with Skinvisible Inc; consulting agreements with Axella Research LLC; and a Master Service Agreement with Therapeutics Inc The company was founded in 2018 and is based in Ashburn, Virginia.